Joel Raskin, CMO of Arrivo Bio talks about unlocking the future of psychiatry

from Power to the Patients · host Brandon Li

Brandon Li talks with Joel Raskin, Chief Medical Officer at Arrivo, about his journey from training in psychiatry in Toronto to leading pharmaceutical research in his current role. Joel shares details on SP-624, an Arrivo compound showing promise in treating depression through epigenetic mechanisms. Their deep dive covers the challenges of clinical trials, and the potential for precision psychiatry to revolutionize psychiatry and neuroscience.

Episode metadata supplied by the publisher feed · Published May 23, 2025

Embed this episode

Attribution link and audio player

Ready to play

Joel Raskin, CMO of Arrivo Bio talks about unlocking the future of psychiatry

0:00 47:26

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Power to the Patients?

This episode is 47 minutes long.

When was this Power to the Patients episode published?

This episode was published on May 23, 2025.

Can I download this Power to the Patients episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!